Group 2 innate lymphoid cells (ILC2s) are a recently identified group of cells with the potent capability to produce Th2-type cytokines such as interleukin (IL)-5 and IL-13. Several studies suggest that ILC2s play an important role in the development of allergic diseases and asthma. Activation of pulmonary ILC2s in murine models lacking T and B cells induces eosinophilia and airway hyper-reactivity (AHR), which are cardinal features of asthma. More importantly, numerous recent studies have highlighted the role of ILC2s in asthma persistence and exacerbation among human subjects, and thus, regulation of pulmonary ILC2s is a major area of investigation aimed at curbing allergic lung inflammation and exacerbation. Emerging evidence reveals that a group of regulatory T cells, induced Tregs (iTregs), effectively suppress the production of ILC2-driven, pro-inflammatory cytokines IL-5 and IL-13. The inhibitory effects of iTregs are blocked by preventing direct cellular contact or by inhibiting the ICOS-ICOS-ligand (ICOSL) pathway, suggesting that both direct contact and ICOS-ICOSL interaction are important in the regulation of ILC2 function. Also, cytokines such as IL-10 and TGF-b1 significantly reduce cytokine secretion by ILC2s. Altogether, these new findings uncover iTregs as potent regulators of ILC2 activation and implicate their utility as a therapeutic approach for the treatment of ILC2-mediated allergic asthma and respiratory disease.
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Type 2 immunity
Type 2 immunity, characterized by high antibody titers and interleukin (IL) production (specifically, IL-4, IL-5, IL-9, IL-10, and IL-13), provides host protection against helminthic infections. However, imbalance of this system triggers allergic disorders such as reactive airway disease, asthma, eczema, allergic rhinitis, and food allergies (1, 2) . The type 2 immune response involves an ever-expanding repertoire of innate immune cells, including Th2 cells, regulatory T cells (Tregs), natural killer (NK) cells, NKT cells, basophils, eosinophils, mast cells, macrophages, and the group 2 innate lymphoid cells (ILC2s) (3) . In this review, we focus our attention on two cell types that are instrumental in type 2 immunity, ILC2s and Tregs, and their reciprocal interactions, which recent findings suggest are key targets for treating type 2 immune disease.
Group 2 innate lymphoid cells (ILC2s)
ILCs are a subset of leukocytes that exhibit a lymphoid morphology but lack the lymphocyte lineage markers and the V (D)J recombination that occurs in T and B lymphocytes. They are divided into three groups based on their patterns of transcription factor expression and cytokine secretion (4): ILC1s, which express T-bet and produce IFN-c and tumor necrosis factor (TNF); ILC2s, which require trans-acting T cell-specific transcription factor (GATA-3) and RAR-related orphan receptor alpha (RORa), and secrete IL-4, IL-5, IL-9 and IL-13; and ILC3s, which require RORct and produce IL-17 and IL-22 (4). ILC2s in particular are known for their roles in helminth infections and airway hyper-reactivity (AHR). Despite lacking the typical lymphoid lineage markers, ILC2s can still be identified based on a profile of surface molecules. In mice, ILC2s are identified by their high expression of CD25, CD44, Thy1.2, ICOS, ICOS-L, Sca-1, and IL-7Ra (5). Human ILC2s reliably express CD45, CD161, CRTH2, ST2, GATA3, ICOS, and ICOS-L (6, 7), although their phenotypic profile varies among mucosal, pathological, and nonpathological tissues (8) . Predictably, the number and function of these cells can change in disease states. For example, patients with allergic asthma have a higher prevalence of ILC2s in their blood and produce larger amounts of IL-5 and IL-13 in response to IL-33 or IL-25, when compared to healthy control participants or patients with allergic rhinitis (9) .
ILC2s in allergic respiratory disease
Asthma is an obstructive airway disease that causes acute and chronic inflammation, AHR, and airway remodeling (10) , producing symptoms of wheezing, chest tightness, and cough in as many as 334 million sufferers worldwide (11) . Cytokines secreted by Th2 cells, IL-4, IL-5, IL-9, and IL-13, are involved in allergic asthma (12, 13) , and as previously mentioned, these 'type 2' cytokines, primarily IL-5 and IL-13, are also vigorously produced by ILC2s exposed to IL-25 or IL-33 (5, 14) . The first indication for the presence of ILC2s in humans with allergic asthma came from the 2009 observation of CD34+ cells in peripheral blood that expressed receptors for TSLP and IL-33, and robustly produced Th2 cytokines (15) . Subsequently, this population was also characterized as positive for CRTH2, CD127, and CD161 (16) . Further studies showed that in addition to epithelial cell-derived cytokines IL-25, IL-33, and TSLP (17) , intranasal administration of house dust mite (HDM) (18, 19) , chitin (20) , or Alternaria alternata (21), as well as infection with influenza (22, 23) or helminths (24) , induces ILC2s to produce large amounts of IL-5 and IL-13, leading to activation of eosinophils and induction of AHR, respectively. Soluble factors such as prostaglandins and leukotrienes, which are central to the asthmatic reaction, have also been stated to robustly influence ILC2s (25, 26) . Moreover, asthma susceptibility has been associated with genetic variants of genes encoding proteins involved in ILC2 activation, for example, TSLP, IL-17RB, IL-33, and ST2 (8, (27) (28) (29) (30) .
Murine models have been useful in defining the contributions of ILC2s to the development of respiratory inflammation. In a murine model of influenza, it was shown that ILC2s were required for AHR development (22) . The comparison of Rag2 À/À mice (which lack T, B) with Rag2 ILCs) has allowed investigators to delineate the involvement of ILC2s in promoting eosinophilia independent of adaptive immune system contribution (31) . Rag2
also been used as cell recipients to study the role of ILC2s in pulmonary inflammation (32, 33) . RORa fl/fl IL7R Cre mice lack the retinoid-related orphan receptor alpha (RORa) that is critical for the development of ILC2s (34) (35) (36) , rendering these animals also ILC2 deficient. Although the perturbation of GATA-3 expression manifests differently in mice as opposed to humans (37) , animals bred for haplo-insufficiency of this key ILC2 transcription factor have proven useful to study the importance of GATA-3 expression for pulmonary eosinophilia, airway hyper-responsiveness, and mucus metaplasia (34) . The elimination of both T cells and ILC2s in a lethal irradiation and transplantation murine model of asthma likewise showed the necessity for ILC2s in airway inflammation and hyper-reactivity (38) . Studies on ILC2s in humans show the frequency of ILC2s is dramatically increased in asthmatic patients (39) . Cells derived from the peripheral blood of patients with allergic asthma secrete significantly more IL-5 and IL-13 than those obtained from healthy controls or even patients with allergic rhinitis, indicating that there are differences in pathogenicity that are specific to asthma and not due to generalized inflammation (9) . Additionally, recent data from Lombardi et al. show that the frequency of ILC2s is increased in allergic vs nonallergic subjects and that in allergic patients, transcription factors FOS, FOSB, and JUN, and CCR10, a homing receptor, are upregulated, the latter of which the authors suggest could be responsible for increased trafficking of ILC2s to the lungs (40) .
In addition to their presence in the lungs and peripheral blood, ILC2s may also be found in human nasal tissues (16) and are found in increased numbers in patients with chronic rhinosinusitis (CRS) (41) . In CRS patients, there exists a Th2 polarization that correlates with severity of signs and symptoms (42) . Patients with both CRS and nasal polyps exhibit a greater infiltration of inflammatory cells, particularly ILC2s, and sustain higher levels of IL-5 and IL-13, when compared to CRS patients without polyps, and to healthy controls (41) . Given that ILC2s secrete IL-5 and IL-13, leading to eotaxin production and eosinophil accumulation, these findings are unsurprising. However, conversely in the patients of that study, transcripts of pro-inflammatory cytokine IL-25 and key ILC2 transcription factor GATA-3 were actually downregulated, although former reports suggest otherwise (43, 44) .
Several transcription factors, STAT6, GATA-3, and ETS-1, contribute to ILC2 proliferation and Th2-type responses in allergic asthma (21) . ILC2s, unlike RORct(+) ILCs, require GATA-3 for their differentiation and maintenance (45) . ILC2s also express the cysteinyl leukotriene receptor 1 (CysLT1R), which when stimulated leads to ILC2 production of IL-4, IL-5, and IL-13; ILC2 proliferation; and Alternariainduced eosinophilia (25) , all of which exacerbate airway inflammation. Leukotriene antagonists also provide relief to sufferers of chronic obstructive pulmonary disease (COPD) via the same receptor mechanism (46) . Leukotrienes act as chemoattractants for other immune cells (47) , increasing trafficking to areas of inflammation. Like ILC2s, Th1, Th2, and especially Th17 cells express CysLT1R, as well as other leukotriene receptor types (48) . These receptors are particularly lacking in one type of T cell, the regulatory T cell.
Discovery, classification, and isolation of regulatory T cells
Research into the cellular biology of human autoimmune diseases led to the observation that a population of CD4 + CD25
+ cells actively suppress other immune cells involved in inflammatory responses, thus allowing the body to achieve a physiological balance of tolerance (49) . The majority of these cells, both in mice and in humans, were later found to express the transcription factor Foxp3 (50), mutations of which cause the multisystemic autoimmune sequelae that manifest as scurfy in mice (51) and IPEX (immunodysregulation polyendocrinopathy enteropathy X-linked syndrome) in humans (52) . These Foxp3 + T cells were found to both reliably suppress autoimmune responses and inhibit physiological immune responses to autologous tumor cells (53); they were subsequently dubbed 'regulatory T cells' or Tregs.
Regulatory T cells have since been further classified based on the site and mechanism of their generation: tTregs, which arise in the thymus; pTregs, which arise in the periphery; and iTregs, which are induced in cell culture via TCR stimulation with interleukin (IL)-2 and transforming growth factor beta (TGF-b) (54) (55) (56) 
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À ) nonsuppressive memory cells that also express Foxp3 (61).
The role of tregs in asthma
The role of regulatory T cells in asthma was demonstrated before Tregs were described in the literature. When mice were exposed to aerosolized protein intranasally, transient IgE production and T-cell proliferation were elicited (62, 63) , but when the animals were later challenged intraperitoneally with the same protein, IgE levels and T-cell proliferation were markedly decreased when compared to the negative controls. This suppression was later found to be due to the induction of regulatory T cells, as repeated exposure of mice to lowdose allergen promotes the development of a regulatory CD4+ T-cell population that expresses membrane-bound TGF-b and Foxp3 (64) . Regulatory T cells have been shown to be active in the preservation of immune homeostasis (65) and exert tolerance by regulating effector cells, albeit displaying considerable heterogeneity in genetic expression and function. The functional repertoire of regulatory T cells includes tolerance to self-antigens and prevention of autoimmunity, which involves inhibition of Th2-driven immune responses, such as those which lead to AHR in asthma (66) . Precisely how Tregs suppress these Th2-driven responses is not yet clear, and it is likely that several distinct mechanisms are important. Deficiency of extrathymic (induced) Tregs in mice causes allergic inflammation at mucosal sites, including unprovoked airway pathway pathology similar to that seen in patients with asthma (67) . Glucocorticoids, which are standard treatments for asthma, increase Foxp3 expression in asthmatic patients (68) , indicating that increasing Foxp3 + Tregs may be instrumental for these agents' anti-inflammatory actions; however, systemic administration of corticosteroids significantly impairs Treg development in animal models (69) . In human subjects, the number of CD25 (73) . The plasticity observed in iTregs can possibly be explained by reports that suggest differential DNA methylation of the CNS2 region, thus determining the stability of the Treg cell (74) .
Production of cytokines such as IL-10 and TGF-b is associated with peripheral T-cell tolerance and the presence of Tregs, enabling Tregs to directly inhibit airway inflammation and AHR (33) . The maintenance of Tregs in the periphery and their expression of Foxp3 require TGF-b1 (75) . Also, TGF-b complexed with latency-associated peptide (LAP) on the cell surface of some Tregs suppresses activated T-cell proliferation, but not na€ ıve T-cell activation (76) . Tregs that express LAP demonstrate more robust suppressive capabilities than those which lack it (77).
During development, nTregs require strong CD28 stimulation (78), whereas iTregs mature under weak CD28 stimulation yet need CTLA-4 costimulation (79) . Both CD28 and CTLA-4 belong to the same superfamily that includes another important cell surface protein, inducible T-cell costimulator (ICOS) (80) , a molecule that is present on both 
Direct contact and ICOS:ICOS-L interaction are integral for Treg-mediated ILC2 suppression
Very recently, our group showed that iTregs are sufficient to suppress ILC2-driven inflammation in murine models (33) . Our group has demonstrated that in both in vitro and in vivo experiments, iTregs, but not nTregs, effectively suppress the production of ILC2-driven, pro-inflammatory cytokines and attenuate pulmonary inflammation. Specifically, addition of iTregs, but not nTregs or effector T cells, to an in vitro culture of ILC2s dramatically reduces the ILC2 production of type 2 cytokines IL-5 and IL-13. The fact that iTregs were implicated as the relevant subtype corroborates with the existing literature indicating that iTregs, as opposed to nTregs, drive suppression of effector T-cell events in murine models of asthma (87, 95) .
The colocalization of ILC2s and Tregs in lung tissue (14, 96) after the induction of airway hyper-reactivity led us to further investigate a relationship between Tregs and ILC2s that required proximity or direct contact. Consistent with the literature, our permeable membrane studies indicate that the suppression of ILC2s by Tregs is contact dependent (33, 97) . Further investigations into the molecules involved in this contact dependency led our group and others to describe the presence of both ICOS and ICOS-L on ILC2s (6, 94) , and the apparent interaction of ICOS-L on ILCs with ICOS on Tregs (33, 94) (Fig. 1 From bench to bedside: humanized models of ILCdependent asthma A major breakthrough in the generation of humanized mice was the development of immunodeficient mice bearing a targeted IL-2Rc mutation. These mice permit functional in vivo studies of human cells and tissues (101) . Models have been developed in which immunodeficient alymphoid mice are 'humanized', either by adoptive transfer of sorted human ILCs (6, 33, 102) , or by introduction of human hematopoietic stem cells in the context of intestinal inflammation (103) . These animals can be challenged with allergens or other stimuli, after which disease phenotypes, such as airway hyper-reactivity (AHR) and eosinophilia, can be measured. This system allows us to study the cellular or molecular pathways that target ILC2s. Utilizing this humanized murine model, we performed adoptive transfer of iTregs and observed that syngeneic iTregs result in ILC2 suppression, as evidenced by reduced AHR and eosinophilia (33) . This suppression was dependent on ICOS/ICOS-L interactions, as treatment of recipients with blocking antibody against human ICOS-L abrogated iTreg suppression. These studies confirm our prior findings in murine models suggesting the importance of iTregs in suppressing ILC2s.
Future directions and conclusions
Reducing Th2 cytokines and regulating ILC2s are two potential treatment strategies aimed at controlling allergic asthmatic disease without instigating generalized immunosuppression (104) . Recent contributions to the literature discussed herein suggest that targeting the ICOS:ICOS-L axis could provide relief to sufferers of asthma by tempering the inflammatory consequences of ILC2 activation. Yet, therapeutic agents aimed at blocking this interaction would have to do so without eliciting a complete impediment of Treg function, as without functional Tregs, unopposed effector T cells would likely effect the autoimmune sequelae seen in IPEX syndrome. The development of selective antagonizing antibodies against ICOS-L on ILC2s is a rational start point to begin modulation of the ICOS: ICOS-L interaction. Also, humanized mouse models, such as those developed recently, provide an apt testing system to evaluate potential treatments before introducing into human subjects (6, 33) . Several forms of Tregs are effective in limiting allergic inflammation and asthma, including both nTregs and iTregs. Recent studies suggest that Treg cells of thymic vs extrathymic origin have distinct mechanistic requirements for differentiation and exert specialized functions in immune homeostasis. Through direct cellular contact and the ICOS-ICOSL axis, extrathymically derived iTregs play an essential role in controlling ILC2-driven AHR characteristic of allergic asthma. Immunotherapy utilizing iTregs may provide safe, specific, and long-lasting control of ILC2-dependent asthmatic disease. Humanized mouse models have led to further understanding of the mechanisms involved to induce iTregs, and continued research in this area promises to expand the utilization of these cells into effective therapy.
